Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses

Figure 4 Combined blockade increased the percentage of CD4⁺ and CD8⁺ T cells in mice. A-C: The percentage of CD4+ T cells in tumor tissues (A), peripheral blood (B) and spleen (C) of mice in four groups was tested with flow cytometry. E and F: The percentage of CD8+ T cells in (D) tumor tissues, peripheral blood (E) and spleen (F) of mice in four groups was tested with flow cytometry. Data from at least three independent experiments were presented as mean ± SD. ^aP < 0.01, ^bP < 0.01, ^cP < 0.01, compared with the immunoglobulin G isotype control group. PD-1: Programmed cell death protein 1; TIM-3: T cell immunoglobulin and mucin domain-containing protein 3; IgG: Immunoglobulin G; mAb: Monoclonal antibody.